OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.16 EUR 1.18% Market Closed
Market Cap: 115.9m EUR

OSE Immunotherapeutics SA
Total Liabilities & Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

OSE Immunotherapeutics SA
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Total Liabilities & Equity
€104m
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
18%
Valneva SE
PAR:VLA
Total Liabilities & Equity
€448m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Total Liabilities & Equity
€45m
CAGR 3-Years
-18%
CAGR 5-Years
0%
CAGR 10-Years
3%
Inventiva SA
PAR:IVA
Total Liabilities & Equity
€179m
CAGR 3-Years
18%
CAGR 5-Years
21%
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Total Liabilities & Equity
$143m
CAGR 3-Years
-21%
CAGR 5-Years
-15%
CAGR 10-Years
2%
Abivax SA
PAR:ABVX
Total Liabilities & Equity
€120m
CAGR 3-Years
19%
CAGR 5-Years
19%
CAGR 10-Years
N/A
No Stocks Found

OSE Immunotherapeutics SA
Glance View

Market Cap
113.5m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
Not Available

See Also

What is OSE Immunotherapeutics SA's Total Liabilities & Equity?
Total Liabilities & Equity
104m EUR

Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Total Liabilities & Equity amounts to 104m EUR.

What is OSE Immunotherapeutics SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
18%

Over the last year, the Total Liabilities & Equity growth was -26%. The average annual Total Liabilities & Equity growth rates for OSE Immunotherapeutics SA have been 1% over the past three years , 3% over the past five years , and 18% over the past ten years .

Back to Top